Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Assets Average (2016 - 2025)

Aptevo Therapeutics' Assets Average history spans 10 years, with the latest figure at $21.3 million for Q3 2025.

  • For Q3 2025, Assets Average rose 41.75% year-over-year to $21.3 million; the TTM value through Sep 2025 reached $21.3 million, up 41.75%, while the annual FY2024 figure was $20.2 million, 31.54% down from the prior year.
  • Assets Average for Q3 2025 was $21.3 million at Aptevo Therapeutics, up from $12.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $70.1 million in Q2 2021 and bottomed at $12.0 million in Q1 2025.
  • The 5-year median for Assets Average is $31.9 million (2023), against an average of $34.4 million.
  • The largest annual shift saw Assets Average skyrocketed 220.5% in 2021 before it tumbled 49.05% in 2024.
  • A 5-year view of Assets Average shows it stood at $60.3 million in 2021, then crashed by 45.35% to $33.0 million in 2022, then decreased by 21.15% to $26.0 million in 2023, then tumbled by 40.86% to $15.4 million in 2024, then soared by 38.66% to $21.3 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Assets Average are $21.3 million (Q3 2025), $12.0 million (Q2 2025), and $12.0 million (Q1 2025).